Regulatory mechanisms and therapeutic potential of N6-methyladenosine modification in retinal diseases (Review)

N6-Methyladenosine (m6A) modification, the most abundant internal chemical modification in eukaryotic messenger RNA, plays a central role in gene expression by dynamically regulating RNA metabolism.The present review systematically summarizes the regulatory mechanisms and pathological significance of m6A modification in major retinal diseases, including diabetic retinopathy, age-related macular degeneration, retinoblastoma, uveitis and retinitis pigmentosa.Studies indicate that m6A methyltransferases (METTL3), demethylases (FTO and ALKBH5) and reader proteins (the YTH domain-containing family of proteins) participate in pathological processes such as angiogenesis, inflammatory responses, pyroptosis and photoreceptor degeneration by modulating the stability, translation efficiency and degradation of key gene mRNAs.Furthermore, this review explores the therapeutic potential of targeting m6A-modifying enzymes (for example, small-molecule inhibitors STM2457 and FB23-2) and highlights challenges in tissue specificity, delivery systems and clinical translation.Future research should integrate multi-omics technologies and precision intervention strategies to advance the application of m6A modification in the diagnosis and treatment of retinal diseases.Contents 1. Introduction 2. Role of m6A modification in DR 3. Role of m6A modification in AMD 4. Role of m6A modification in RB and uveitis: Current evidence and limitations 5. Role of m6A modification in RP 6. Discussion and future perspectives 7. Conclusion